盐酸度洛西汀FDA说明书(英文).pdf

1 HIGHLIGHTS OF PRESCRIBING INFORMATION days of stopping an MAOI intended to treat psychiatric disorders. These highlights do not include all the information needed to use In addition, do not start Cymbalta in a patient who is being treated CYMBALTA safely and effectively. See full prescribing with linezolid or intravenous methylene blue (4.1) information for CYMBALTA. • Use in patients with uncontrolled narrow-angle glaucoma (4.2) CYMBALTA (duloxetine hydrochloride) Delayed-Release Capsules WARNINGS AND PRECAUTIONS for Oral Use. Initial U.S. Approval: 2004 • Suicidality: Monitor for clinical worsening and suicide risk (5.1) • Hepatotoxicity: Hepatic failure, sometimes fatal, has been WARNING: SUICIDAL THOUGHTS AND BEHAVIORS reported in patients treated with Cymbalta. Cymbalta should be See full prescribing information for complete boxed warning. discontinued in patients who develop jaundice or other evidence • Increased risk of suicidal thinking and behavior in children, of clinically significant liver dysfunction and should not be adolescents, and young adults taking antidepressants (5.1) res